Cargando…

Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine

The candidate malaria vaccine RTS,S has demonstrated 45.7% efficacy over 18 months against all clinical disease in a phase-III field study of African children. RTS,S targets the circumsporozoite protein (CSP), which is expressed on the Plasmodium sporozoite during the pre-erythrocyte stage of its li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moris, Philippe, Jongert, Erik, van der Most, Robbert G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791571/ https://www.ncbi.nlm.nih.gov/pubmed/28934066 http://dx.doi.org/10.1080/21645515.2017.1381809

Ejemplares similares

Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial
por: van den Berg, Robert A., et al.
Publicado: (2017)

T Cell Responses to the RTS,S/AS01(E) and RTS,S/AS02(D) Malaria Candidate Vaccines Administered According to Different Schedules to Ghanaian Children
por: Ansong, Daniel, et al.
Publicado: (2011)

A Statistical Interaction between Circumsporozoite Protein-Specific T Cell and Antibody Responses and Risk of Clinical Malaria Episodes following Vaccination with RTS,S/AS01E
por: Ndungu, Francis M., et al.
Publicado: (2012)

The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity
por: Chaudhury, Sidhartha, et al.
Publicado: (2016)

Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01(E) and Protection against P falciparum Clinical Malaria
por: Olotu, Ally, et al.
Publicado: (2011)

Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis
por: Chaudhury, Sidhartha, et al.
Publicado: (2017)

Safety and immunogenicity of candidate vaccine M72/AS01(E) in adolescents in a TB endemic setting
por: Penn-Nicholson, Adam, et al.
Publicado: (2015)

The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01(E) on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants
por: Ajua, Anthony, et al.
Publicado: (2015)

RTS,S: the first malaria vaccine
por: Zavala, Fidel
Publicado: (2022)

Randomized Controlled Trial of RTS,S/AS02(D) and RTS,S/AS01(E) Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children
por: Owusu-Agyei, Seth, et al.
Publicado: (2009)

Correction: Randomized Controlled Trial of RTS,S/AS02(D) and RTS,S/AS01(E) Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children
por: Owusu-Agyei, Seth, et al.
Publicado: (2010)

Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01(E) malaria vaccine in African children: a randomized trial
por: Valéa, Innocent, et al.
Publicado: (2020)

Induction of Plasmodium falciparum-Specific CD4(+) T Cells and Memory B Cells in Gabonese Children Vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D)
por: Agnandji, Selidji T., et al.
Publicado: (2011)

The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection
por: Du, Ying, et al.
Publicado: (2020)

Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial
por: Valéa, Innocent, et al.
Publicado: (2018)

Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes
por: Miura, Kazutoyo, et al.
Publicado: (2014)

Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01(E) on Blood Stage Immunity in Young Children
por: Bejon, Philip, et al.
Publicado: (2011)

The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01
por: Fortpied, Juliette, et al.
Publicado: (2020)

RTS,S Malaria Vaccine and Increased Mortality in Girls
por: Klein, Sabra L., et al.
Publicado: (2016)

Impact of the RTS,S Malaria Vaccine Candidate on Naturally Acquired Antibody Responses to Multiple Asexual Blood Stage Antigens
por: Campo, Joseph J., et al.
Publicado: (2011)

Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials
por: Young, William Chad, et al.
Publicado: (2021)

A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01(E) and RTS,S/AS01(B) Delayed Fractional Dose Regimens in Malaria-Naive Adults
por: Moon, James E, et al.
Publicado: (2020)

Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01(E) in Young Children
por: Olotu, Ally, et al.
Publicado: (2014)

Potential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling study
por: Sauboin, Christophe J., et al.
Publicado: (2015)

Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on Genotypes of P. falciparum in Adults Participating in a Malaria Vaccine Clinical Trial
por: Waitumbi, John N., et al.
Publicado: (2009)

A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses
por: Pallikkuth, Suresh, et al.
Publicado: (2020)

A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon
por: Lell, Bertrand, et al.
Publicado: (2009)

The RTS,S malaria vaccine: Journey from conception to recommendation
por: Egbewande, Oluwaseyi Muyiwa
Publicado: (2022)

RTS,S malaria vaccine pilot studies: addressing the human realities in large-scale clinical trials
por: van den Berg, Machteld, et al.
Publicado: (2019)

Assessment of genetic diversity of Plasmodium falciparum circumsporozoite protein in Sudan: the RTS,S leading malaria vaccine candidate
por: Mohamed, Nouh Saad, et al.
Publicado: (2021)

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults
por: Ockenhouse, Christian F., et al.
Publicado: (2015)

Policy analysis for deciding on a malaria vaccine RTS,S in Tanzania
por: Romore, Idda, et al.
Publicado: (2016)

The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan
por: Gosling, Roly, et al.
Publicado: (2016)

Safety of the Malaria Vaccine Candidate, RTS,S/AS01(E) in 5 to 17 Month Old Kenyan and Tanzanian Children
por: Lusingu, John, et al.
Publicado: (2010)

The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01(E) Malaria Vaccine( )
por: Sagara, Issaka, et al.
Publicado: (2021)

A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults
por: Kumarasamy, Nagalingeswaran, et al.
Publicado: (2016)

Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette–Guérin-Vaccinated Adults
por: van den Berg, Robert A., et al.
Publicado: (2018)

Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care
por: Vekemans, Johan, et al.
Publicado: (2011)

Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program
por: Baral, Ranju, et al.
Publicado: (2023)

The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease
por: Penny, Melissa A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bk05f5vbbjrf6k2re2lo1qmfsq